Excessive exposure to anionic surfaces maintains autoantibody response to β2-glycoprotein I in patients with antiphospholipid syndrome

Blood

Volumn 110, Issue 13, 2007, Pages 4312-4318

  Yamaguchi, Yukie ^a,b   Seta, Noriyuki ^a   Kaburaki, Junichi ^c   Kobayashi, Kazuko ^d   Matsuura, Eiji ^d   Kuwana, Masataka ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TOKYO ELECTRIC POWER COMPANY   (Japan)

^d OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; FC RECEPTOR; HLA DR ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; LIPOSOME; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID BINDING PROTEIN; ANION; LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLSERINE;

ABORTION; ADULT; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; THROMBOSIS; AUTOIMMUNITY; CELL CULTURE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MONOCYTE; T LYMPHOCYTE; THROMBOCYTE;

ANIONS; ANTIGEN PRESENTATION; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; AUTOIMMUNITY; BETA 2-GLYCOPROTEIN I; BLOOD PLATELETS; CELLS, CULTURED; HUMANS; LIPOPROTEINS, LDL; LYMPHOCYTE ACTIVATION; MONOCYTES; PHOSPHATIDYLSERINES; T-LYMPHOCYTES;

EID: 38049023658     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-07-100008     Document Type: Article

References (38)

1. Harris EN, Chan JK, Asherson RA, Aber VR, Gharavi AE, Hughes GRV. Thrombosis, recurrent fetal loss, and thrombocytopenia: predictive value of the anticardiolipin antibody test. Arch Intern Med. 1986;146:2153-2156.
2. 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990;87:4120-4124.
3. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 1990;335:1544-1547.
4. 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays.Am J Med. 1996;101:472-481.
5. 2-glycoprotein I (apolipoprotein H) interactions with phospholipid vesicles. Int J Biochem. 1984;16:511-515.
6. 2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulant. Blood. 1993;81:1255-1262.
7. 2-glycoprotein I and induce endothelial activation. Arthritis Rheum. 1997;40:551-561.
8. 2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice. J Autoimmun. 1994;7:441-455.
9. Levy Y, Ziporen L, Gilburd B, et al. Membranous nephropathy in primary antiphospholipid syndrome: description of a case and induction of renal injury in SCID mice. Hum Antibodies Hybridomas. 1996;7:91-96.
10. 2-glycoprotein I in patients with antiphospholipid syndrome and healthy individuals. Arthritis Rheum. 2000;43:65-75.
11. 2-glycoprotein I in patients with antiphospholipid syndrome: preferential recognition of the major phospholipid-binding site. Blood. 2001;98:1889-1896.
12. 2-glycoprotein I in patients with antiphospholipid syndrome. Blood. 2002;99:2499-2504.
13. 2-glycoprotein I contains a phospholipid binding site (Cys281-Lys288) and a region recognized by anticardiolipin antibodies. J Immunol. 1994;152:653-659.
14. 2-glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity. J Immunol. 1996;157:3744-3751.
15. 2- glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood. 2005;105:1552-1557.
16. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
17. Naruse T, Ando R, Nose Y, et al. HLA-DRB4 genotyping by PCR-RFLP: diversity in the associations between HLA-DRB4 and DRB1 alleles. Tissue Antigens. 1997;49:152-159.
18. Matsuura E, Igarashi Y, Fujimoto M, et al. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol. 1992;148:3885-3891.
19. 2-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages. J Lipid Res. 2002;43:1486-1495.
20. 2-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J Lipid Res. 2001;42:697-709.
21. Bogdan W, Urszula K, Lidia M, et al. Comparison of platelet aggregability and P-selectin surface expression on platelets isolated by different methods. Thromb Res. 2000;99:495-502.
22. Nakamura M, Tanaka Y, Satoh T, et al. Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism. Rheumatology (Oxford). 2006;45:150-156.
23. Kuwana M, Okazaki Y, Kaburaki J, et al. Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol. 2002;168:3675-3682.
24. Božič B, Čǔcnik T, Kveder T, Rozman B. Avidity of anti-beta-2-glycoprotein I antibodies. Autoimmunity Rev. 2005;4:303-308.
25. 2-GPI and cardiolipin in patients with systemic lupus erythematosus and primary antiphospholipid syndrome, and their clinical associations. Rheumatology (Oxford). 2001;40:1026-1032.
26. 2-glycoprotein I as the basis for the association between IgG2 anticardiolipin antibodies and thrombosis in the antiphospholipid syndrome. Arthritis Rheum. 1998;41:1513-1514.
27. Simitsek PD, Campbell DG, Lanzavecchia A, Fairweather N, Watts C. Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants. J Exp Med. 1995;181:1957-1963.
28. Wolberg AS, Roubey RAS. Mechanisms of autoantibody-induced monocyte tissue factor expression. Thromb Res. 2004;114:391-396.
29. 2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res. 2003;44:716-726.
30. Matsuura E, Kobayashi K, Koike T, Shoenfeld Y. Autoantibody-mediated atherosclerosis. Autoimmunity Rev. 2002;1:348-353.
31. Shoenfeld A, Gerli R, Doria A, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation. 2005;112:3337-3347.
32. Morel O, Jesel L, Freyssinet JM, Toti F. Elevated levels of procoagulant microparticles in a patient with myocardial infarction, antiphospholipid antibodies and multifocal cardiac thrombosis. Thromb J. 2005;3:15.
33. Ambrozic A, Bozic B, Kveder T, et al. Budding, vesiculation and permeabilization of phospholipid membranes-evidence for a feasible physiologic role of beta2-glycoprotein I and pathogenic actions of anti-beta2-glycoprotein I antibodies. Biochim Biophys Acta. 2005;1740:38-44.
34. Combes V, Simon AC, Grau GE, et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest. 1999;104:93-102.
35. Rubenstein E, Arkfeld DG, Metyas S, Shinada S, Ehresmann S, Liebman HA. Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol. 2006;33:355-357.
36. Cervera R, Font J, Gomez-Puerta JA, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis. 2005;64:1205-1209.
37. Otsubo S, Nitta K, Yumura W, Nihei H, Mori N. Antiphospholipid syndrome treated with prednisolone, cyclophosphamide and double-filtration plasmapheresis. Intern Med. 2002;41:725-729.
38. Braselmann S, Taylor V, Zhao H, et al. R406, an orally available spleen tyrosine kinase inhibitor blockes Fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006;319:998-1008.